STOCK TITAN
  1. Home
  2. Sec-filings
  3. RDHL
  4. [6-K] RedHill Biopharma Ltd. Current Report (Foreign Issuer)

RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

RedHill Biopharma Ltd., a foreign private issuer based in Tel Aviv, reports that at its adjourned Annual General Meeting of Shareholders held on August 7, 2026, all resolutions proposed to shareholders were duly approved. This confirms shareholder support for the full slate of items presented at that meeting.

The company also states that this report is incorporated by reference into multiple existing Registration Statements on Form S-8 and Form F-3, linking the AGM outcomes and related disclosures into its broader U.S. securities registration framework.

Positive

  • None.

Negative

  • None.
Commission File Number 001-35773 SEC registration file number for RedHill Biopharma Ltd.
Adjourned AGM date August 7, 2026 Date when all shareholder resolutions were approved
Latest referenced F-3 filing date July 2, 2026 Most recent Form F-3 registration statement referenced by incorporation
Foreign Private Issuer regulatory
"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Form 6-K regulatory
"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Registration Statements on Form S-8 regulatory
"hereby incorporated by reference into the Company's Registration Statements on Form S-8"
Registration Statements on Form F-3 regulatory
"and its Registration Statements on Form F-3 filed with the Securities"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did RedHill Biopharma (RDHL) report about its August 2026 shareholder meeting?
RedHill Biopharma reported that at its adjourned Annual General Meeting on August 7, 2026, shareholders duly approved all resolutions presented. This indicates formal shareholder backing for every item submitted at that meeting.

When was RedHill Biopharma (RDHL)'s adjourned Annual General Meeting held?
RedHill Biopharma’s adjourned Annual General Meeting of Shareholders was held on August 7, 2026. At this meeting, the company states that shareholders approved all resolutions that had been proposed to them.

Were all resolutions approved at RedHill Biopharma (RDHL)'s 2026 adjourned AGM?
Yes. RedHill Biopharma states that all resolutions proposed to shareholders at the adjourned Annual General Meeting on August 7, 2026, were duly approved, meaning none of the items presented failed to secure approval.

How is this RedHill Biopharma (RDHL) AGM report used in its SEC registrations?
RedHill Biopharma states that this report is incorporated by reference into multiple Form S-8 and Form F-3 registration statements. This allows the AGM-related information to be treated as part of those registration documents.

What type of SEC filer is RedHill Biopharma (RDHL) in this report?
RedHill Biopharma is described as a foreign private issuer submitting a Form 6-K for August 2026. This form is used by non-U.S. companies to furnish important information under U.S. securities laws.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 

of the Securities Exchange Act of 1934

 

For the month of August 2026


Commission File No.:001-35773

 

REDHILL BIOPHARMA LTD. 

(Translation of registrant’s name into English)

 

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel 

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

 

Form 20-F ☒        Form 40-F ☐

 

 

At the adjourned Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”) held on August 7, 2026, all of the resolutions proposed to the shareholders were duly approved. Below are the proposals adopted:

 

1.To re-appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2026 and for an additional period until the next Annual General Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2025;

 

2.To approve the re-election of Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the board of directors of the Company (the “Board of Directors”) for an additional three-year term until the annual general meeting to be held in 2029;

 

3.To approve the engagement by the Company of Mr. Dror Ben-Asher to serve as the Company's Chairman of the Board of Directors and the Company's Chief Executive Officer; and

 

4.To amend the Company’s Articles of Association to eliminate the par value of the Company’s shares.

 

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  

 

  REDHILL BIOPHARMA LTD.  
  (the “Registrant”)  
       
Date: August 7, 2026 By: /s/ Dror Ben-Asher  
  Name: Dror Ben-Asher  
  Title: Chief Executive Officer  

 

 

 

Source: View Original Filing on SEC EDGAR